 |
|
Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
Alexandra Cohen, Najma Ahmed, Ana Sant’Anna
Intest Res. 2021;19(2):217-224. Published online 2020 Apr 22 DOI: https://doi.org/10.5217/ir.2019.09164
|
|
Citations to this article as recorded by
 Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
Abdulhamid Alhadab, Amal Almarhoon, Amena AlAlwan, AbdelHai Hammo
Saudi Journal of Gastroenterology.2024;[Epub] CrossRef Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intestinal Research.2023; 21(1): 137. CrossRef Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
Shengbo Fang, Sixi Zhang, Chunyan Zhang, Libo Wang
Pediatric Drugs.2023; 25(5): 499. CrossRef Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review
Phinga Do, John Andersen, Ashish Patel, Gaith Semrin, Luis Sifuentes-Dominguez, Phuong Luu, Bhaskar Gurram
F1000Research.2021; 9: 316. CrossRef Ustekinumab Dose Intensification in Paediatric Crohn's Disease
Rosa Rodríguez‐Mauriz, Carlos Seguí Solanes, Isabel Masiques Mas, Nuria Rudi Sola
Journal of Paediatrics and Child Health.2021; 57(7): 1148. CrossRef
|